Literature DB >> 23254179

Autologous fat transplantation to the velopharynx for treating persistent velopharyngeal insufficiency of mild degree secondary to overt or submucous cleft palate.

Charles Filip1, Michael Matzen, Ingegerd Aagenæs, Ragnhild Aukner, Lillian Kjøll, Hans Erik Høgevold, Kim Tønseth.   

Abstract

BACKGROUND: Autologous fat transplantation to the velopharynx has been described in a few smaller studies including heterogeneous groups of patients for the treatment of velopharyngeal insufficiency (VPI). The aim of this study was to evaluate speech and to measure velopharyngeal closure with magnetic resonance imaging (MRI) in patients who underwent autologous fat transplantation for the treatment of persistent VPI of mild degree secondary to overt or submucous cleft palate.
METHODS: A prospective study of 16 patients with persistent VPI of mild degree secondary to overt or submucous cleft palate who underwent autologous fat transplantation to the velopharynx. The patients were injected with a median of 5.6 (3.8-7.6) ml autologous fat to the velopharynx. Pre- and 1-year postoperative audio recordings were blinded for scoring independently by three senior speech therapists. Hypernasality, hyponasality, nasal turbulence and audible nasal emission were scored on a five-point scale. Pre- and 1-year postoperative MRIs were obtained during vocal rest and during phonation in 12 patients. Data measured were the velopharyngeal distance in the sagittal plane and the velopharyngeal gap area in the axial plane.
RESULTS: Hypernasality improved significantly (p=0.030), but not audible nasal emission (p=0.072) or nasal turbulence (p=0.12). The velopharyngeal distance during phonation decreased significantly (p=0.013), but not the velopharyngeal gap area (p=0.16). There was no significant correlation between speech and MRI results.
CONCLUSION: Autologous fat transplantation to the velopharynx improved hypernasality significantly, but not audible nasal emission or nasal turbulence in patients with persistent VPI of mild degree secondary to overt or submucous cleft palate. Given the low number of patients and the lack of a control group, the value of fat transplantation for the treatment of mild VPI is not proven for sure.
Copyright © 2012 British Association of Plastic, Reconstructive and Aesthetic Surgeons. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23254179     DOI: 10.1016/j.bjps.2012.11.006

Source DB:  PubMed          Journal:  J Plast Reconstr Aesthet Surg        ISSN: 1748-6815            Impact factor:   2.740


  5 in total

1.  Treatment of congenital short palate using bilateral buccal musculomucosal flaps.

Authors:  Shinji Kobayashi; Yukie Ohashi; Ryouko Fukushima; Takashi Hirakawa; Toshihiko Fukawa; Toshihiko Satake; Jiro Maegawa
Journal:  Case Reports Plast Surg Hand Surg       Date:  2020-05-06

2.  Evaluation of sites of velopharyngeal structure augmentation in dogs for improvement of velopharyngeal insufficiency.

Authors:  Emiko Tanaka Isomura; Kiyoko Nakagawa; Makoto Matsukawa; Ryou Mitsui; Mikihiko Kogo
Journal:  PLoS One       Date:  2019-02-25       Impact factor: 3.240

3.  Autologous fat grafting in the treatment of velopharyngeal insufficiency: Clinical outcomes and treatment tolerability survey in a case series of 21 patients.

Authors:  Renzo Panizza; Marco Ghiglione; Enrico Maria Zingarelli; Michela Massa; Claudio Carlini; Rossella Arnoldi; Alessio Pini Prato; Silvia Scarrone; Francesco Vaccarella
Journal:  Indian J Plast Surg       Date:  2018 May-Aug

4.  Assessment of outcomes and complications of posterior pharyngeal wall augmentation with dermal fat graft in patients with Velopharyngeal Insufficiency (VPI) after primary cleft palate repair: A pilot study.

Authors:  Hossein Abdali; Mohammad Yaribakht
Journal:  JPRAS Open       Date:  2018-10-26

5.  Protocol for the development of a core outcome set for reporting outcomes of management of velopharyngeal dysfunction.

Authors:  Catherine de Blacam; Adriane L Baylis; Richard E Kirschner; Susan M Smith; Debbie Sell; Kathleen C Y Sie; Helen E Harris; David J A Orr
Journal:  BMJ Open       Date:  2020-08-13       Impact factor: 2.692

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.